Drug intelligence / Profile preview

7,8-dihydroflavone

Development stage: Preclinical
Lead developer: Children's Hospital of Philadelphia
Modality: Small Molecules
Administration: Oral, Subcutaneous, Intraperitoneal

Overview

7,8-Dihydroflavone (7,8-DHF) is a naturally occurring small molecule drug that acts as a TrkB receptor agonist. It stimulates lung tissue regeneration by enhancing the STAT3-BDNF-TrkB signaling pathway. This discovery, made through a collaboration between researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania, holds potential for developing new therapies for various lung diseases, including acute respiratory distress syndrome (ARDS) caused by COVID-19.

Other names: 7,8-DHF

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on 7,8-dihydroflavone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7,8-dihydroflavone.

Explore the full profile